{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:09:12Z","timestamp":1791900552441,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jdermsci.2006.12.008","type":"journal-article","created":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T12:12:28Z","timestamp":1169640748000},"page":"53-60","source":"Crossref","is-referenced-by-count":32,"title":["Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid"],"prefix":"10.1016","volume":"46","author":[{"given":"R.","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Asashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Okochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2006.12.008_bib1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2230.1996.tb00006.x","article-title":"Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles","volume":"21","author":"Tanaka","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1172\/JCI115968","article-title":"Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic","volume":"90","author":"Amagai","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib4","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1172\/JCI113803","article-title":"Isolation of complementary DNA for bullous pemphigoid antigen by use of patients\u2019 autoantibodies","volume":"82","author":"Stanley","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib5","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.4049\/jimmunol.145.11.3728","article-title":"IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA","volume":"145","author":"Rico","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","article-title":"Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed","volume":"31","author":"Belgi","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1346-8138.2005.tb00862.x","article-title":"Severe pemphigus vulgaris treated with rituximab (Mabthera)","volume":"32","author":"Cecchi","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2003.08.021","article-title":"Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations","volume":"50","author":"Espana","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"22","author":"Kong","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","article-title":"Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab","volume":"153","author":"Schmidt","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib17","first-page":"ELT24","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib18","first-page":"185","article-title":"Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants","volume":"85","author":"Wenzel","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00128071-200506050-00006","article-title":"Treatment of pemphigus vulgaris: current and emerging options","volume":"6","author":"Yeh","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2005.06672.x","article-title":"Infliximab in the management of severe pemphigus vulgaris","volume":"153","author":"Pardo","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(02)00425-9","article-title":"BAFF\/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2","volume":"17","author":"Kayagaki","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib31","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.173.5.3524","article-title":"Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus","volume":"173","author":"Ramanujam","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/89782","article-title":"TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice","volume":"2","author":"Wang","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/ar1222","article-title":"The current status of targeting BAFF\/BLyS for autoimmune diseases","volume":"6","author":"Ramanujam","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(99)03007-X","article-title":"Pemphigus and bullous pemphigoid","volume":"354","author":"Nousari","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib36","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib37","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jdermsci.2006.12.008_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J Exp Med"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181106003665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181106003665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:15:08Z","timestamp":1683728108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181106003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0923181106003665"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2006.12.008","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}